Apellis surged in retail buzz after the FDA approved Empaveli for two rare kidney diseases. Backed by strong Phase 3 data, the drug targets C3G and IC-MPGN, affecting 5,000 in the US. Analysts at Baird, Morgan Stanley, and BofA raised price targets. On Stocktwits, sentiment was 'extremely bullish' with a 2,350% spike in message volume.